[1]
|
Yi, Q., Liu, Y., Cao, M., Liu, J., Xiang, Q., et al. (2020) Transcriptional Analysis and Differentially Expressed Gene Screening of Spontaneous Liver Tumors in CBA/CaJ Mice. Gene, 725, Article ID: 144159. https://doi.org/10.1016/j.gene.2019.144159
|
[2]
|
Zhang, K., Song, P., Gao, J., Li, G., Zhao, X., et al. (2014) Perspectives on a Combined Test of Multi Serum Biomarkers in China: Towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier Stage. Drug Discoveries & Therapeutics, 8, 102-109. https://doi.org/10.5582/ddt.2014.01026
|
[3]
|
Kumazoe, M., Takai, M., Hiroi, S., Takeuchi, C., Kadomatsu, M., et al. (2017) The FOXO3/PGC-1β Signaling Axis Is Essential for Cancer Stem Cell Properties of Pancreatic Ductal Adenocarcinoma. The Journal of Biological Chemistry, 292, 10813-10823. https://doi.org/10.1074/jbc.M116.772111
|
[4]
|
Wang, P.M., Chung, N.N., Hsu, W.C., Chang, F.L., Jang, C.J., et al. (2015) Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma: Optimal Treatment Strategies Based on Liver Segmentation and Functional Hepatic Reserve. Reports of Practical Oncology and Radiotherapy: Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 20, 417-424. https://doi.org/10.1016/j.rpor.2015.03.005
|
[5]
|
Zhu, J.N., Chen, G.D., Xu, J.Y. and Zhou, X. (2017) Serum AFU, 5’-NT and AFP as Biomarkers for Primary Hepatocellular Carcinoma Diagnosis. Open Medicine (Warsaw, Poland), 12, 354-358. https://doi.org/10.1515/med-2017-0051
|
[6]
|
Giannini, E.G., Sammito, G., Farinati, F., Ciccarese, F., Pecorelli, A., et al. (2014) Determinants of Alpha-Fetoprotein Levels in Patients with Hepatocellular Carcinoma: Implications for Its Clinical Use. Cancer, 120, 2150-2157. https://doi.org/10.1002/cncr.28706
|
[7]
|
Park, H. and Park, J.Y. (2013) Clinical Significance of AFP and PIVKA-II Responses for Monitoring Treatment Outcomes and Predicting Prognosis in Patients with Hepatocellular Carcinoma. BioMed Research International, 2013, Article ID: 310427. https://doi.org/10.1155/2013/310427
|
[8]
|
Notarpaolo, A., Layese, R., Magistri, P., Gambato, M., Colledan, M., et al. (2017) Validation of the AFP Model as a Predictor of HCC Recurrence in Patients with Viral Hepatitis-Related Cirrhosis Who Had Received a Liver Transplant for HCC. Journal of Hepatology, 66, 552-559. https://doi.org/10.1016/j.jhep.2016.10.038
|
[9]
|
Xing, H., Zheng, Y.J., Han, J., Zhang, H., Li, Z.L., et al. (2018) Protein Induced by Vitamin K Absence or Antagonist-Ii versus Alpha-Fetoprotein in the Diagnosis of Hepatocellular Carcinoma: A Systematic Review with Meta-Analysis. Hepatobiliary & Pancreatic Diseases International: HBPD INT, 17, 487-495. https://doi.org/10.1016/j.hbpd.2018.09.009
|
[10]
|
Svobodova, S., Karlikova, M., Topolcan, O., Pecen, L., Pestova, M., et al. (2018) PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma—A Pilot Study. In Vivo (Athens, Greece), 32, 1551-1554. https://doi.org/10.21873/invivo.11413
|
[11]
|
Yu, J.P., Xu, X.G., Ma, R.J., Qin, S.N., Wang, C.R., et al. (2015) Development of a Clinical Chemiluminescent Immunoassay for Serum GPC3 and Simultaneous Measurements alone with AFP and CK19 in Diagnosis of Hepatocellular Carcinoma. Journal of Clinical Laboratory Analysis, 29, 85-93. https://doi.org/10.1002/jcla.21733
|
[12]
|
Abd, E.L., Gawad, I.A., Mossallam, G.I., Radwan, N.H., Elzawahry, H.M., et al. (2014) Comparing Prothrombin Induced by Vitamin K Absence-II (PIVKA-II) with the Oncofetal Proteins Glypican-3, Alpha Feto Protein and Carcinoembryonic Antigen in Diagnosing Hepatocellular Carcinoma among Egyptian Patients. Journal of the Egyptian National Cancer Institute, 26, 79-85. https://doi.org/10.1016/j.jnci.2014.01.001
|
[13]
|
Ahmed-Mohammed, H.F. and Roberts, L.R. (2017) Should AFP (or Any Biomarkers) Be Used for HCC Surveillance? Current Hepatology Reports, 16, 137-145. https://doi.org/10.1007/s11901-017-0349-7
|
[14]
|
Caviglia, G.P., Ribaldone, D.G., Abate, M.L., Ciancio, A., Pellicano, R., et al. (2018) Performance of Protein Induced by Vitamin K Absence or Antagonist-II Assessed by Chemiluminescence Enzyme Immunoassay for Hepatocellular Carcinoma Detection: A Meta-Analysis. Scandinavian Journal of Gastroenterology, 53, 734-740. https://doi.org/10.1080/00365521.2018.1459824
|
[15]
|
Zhang, M., Zhang, Q., Hu, Y., Xu, L., Jiang, Y., et al. (2017) miR-181a Increases FoxO1 Acetylation and Promotes Granulosa Cell Apoptosis via SIRT1 Downregulation. Cell Death & Disease, 8, e3088. https://doi.org/10.1038/cddis.2017.467
|
[16]
|
He, Z., Deng, W., Jiang, B., Liu, S., Tang, M., et al. (2018) Hsa-Let-7b Inhibits Cell Proliferation by Targeting PLK1 in HCC. Gene, 673, 46-55. https://doi.org/10.1016/j.gene.2018.06.047
|
[17]
|
Markant, S.L., Esparza, L.A., Sun, J., Barton, K.L., McCoig, L.M., et al. (2013) Targeting Sonic Hedgehog-Associated Medulloblastoma through Inhibition of Aurora and Polo-Like Kinases. Cancer Research, 73, 6310-6322. https://doi.org/10.1158/0008-5472.CAN-12-4258
|
[18]
|
Xu, L., Zhu, Y., Shao, J., Chen, M., Yan, H., et al. (2017) Dasatinib Synergises with Irinotecan to Suppress Hepatocellular Carcinoma via Inhibiting the Protein Synthesis of PLK1. British Journal of Cancer, 116, 1027-1036. https://doi.org/10.1038/bjc.2017.55
|
[19]
|
Zhang, H., Diab, A., Fan, H., Mani, S.K., Hullinger, R., et al. (2015) PLK1 and Hotair Accelerate Proteasomal Degradation of SUZ12 and ZNF198 during Hepatitis B Virus-Induced Liver Carcinogenesis. Cancer Research, 75, 2363-2374. https://doi.org/10.1158/0008-5472.CAN-14-2928
|
[20]
|
Li, Z., Li, J., Bi, P., Lu, Y., Burcham, G., et al. (2014) PLK1 Phosphorylation of PTEN Causes a Tumor-Promoting Metabolic State. Molecular and Cellular Biology, 34, 3642-3661. https://doi.org/10.1128/MCB.00814-14
|
[21]
|
Takai, N., Hamanaka, R., Yoshimatsu, J. and Miyakawa, I. (2005) Polo-Like Kinases (PLKS) and Cancer. Oncogene, 24, 287-291. https://doi.org/10.1038/sj.onc.1208272
|
[22]
|
Ahr, A., Karn, T., Solbach, C., Seiter, T., Strebhardt, K., et al. (2002) Identification of High Risk Breast-Cancer Patients by Gene Expression Profiling. Lancet (London, England), 359, 131-132. https://doi.org/10.1016/S0140-6736(02)07337-3
|
[23]
|
Kneisel, L., Strebhardt, K., Bernd, A., Wolter, M., Binder, A., et al. (2002) Expression of Polo-Like Kinase (PLK1) in Thin Melanomas: A Novel Marker of Metastatic Disease. Journal of Cutaneous Pathology, 29, 354-358. https://doi.org/10.1034/j.1600-0560.2002.290605.x
|
[24]
|
Eckerdt, F., Yuan, J. and Strebhardt, K. (2005) Polo-Like Kinases and Oncogenesis. Oncogene, 24, 267-276. https://doi.org/10.1038/sj.onc.1208273
|
[25]
|
Tang, Z., Li, C., Kang, B., Gao, G., Li, C., et al. (2017) Gepia: A Web Server for Cancer and Normal Gene Expression Profiling and Interactive Analyses. Nucleic Acids Research, 45, W98-W102. https://doi.org/10.1093/nar/gkx247
|
[26]
|
Holdorf, A.D., Higgins, D.P., Hart, A.C., Boag, P.R., Pazour, G.J., et al. (2019) Caenorhabditis Eleganswormcat: An Online Tool for Annotation and Visualization of Genome-Scale Data. Genetics, 24, 287-291. https://doi.org/10.1101/844928
|
[27]
|
Lv, J. and Li, L. (2019) Hub Genes and Key Pathway Identification in Colorectal Cancer Based on Bioinformatic Analysis. BioMed Research International, 2019, Article ID: 1545680. https://doi.org/10.1155/2019/1545680
|
[28]
|
Kohrman, A.Q. and Matus, D.Q. (2017) Divide or Conquer: Cell Cycle Regulation of Invasive Behavior. Trends in Cell Biology, 27, 12-25. https://doi.org/10.1016/j.tcb.2016.08.003
|
[29]
|
Williams, G.H. and Stoeber, K. (2012) The Cell Cycle and Cancer. The Journal of Pathology, 226, 352-364. https://doi.org/10.1002/path.3022
|
[30]
|
Malumbres, M. and Barbacid, M. (2009) Cell Cycle, Cdks and Cancer: A Changing Paradigm. Nature Reviews. Cancer, 9, 153-166. https://doi.org/10.1038/nrc2602
|
[31]
|
Li, B., Pu, K. and Wu, X. (2019) Identifying Novel Biomarkers in Hepatocellular Carcinoma by Weighted Gene Co-Expression Network Analysis. Journal of Cellular Biochemistry, 26, 79-85. https://doi.org/10.1002/jcb.28420
|
[32]
|
Shen, L.Y. and Lin, C.M. (2019) Plk1 Expression in Mantle Cell Lymphoma and Its Clinical Significance. Journal of Experimental Hematology, 27, 833-838.
|
[33]
|
Haupenthal, J., Bihrer, V., Korkusuz, H., Kollmar, O., Schmithals, C., et al. (2012) Reduced Efficacy of the PLK1 Inhibitor Bi 2536 on the Progression of Hepatocellular Carcinoma Due to Low Intratumoral Drug Levels. Neoplasia (New York, N.Y.), 14, 410-419. https://doi.org/10.1596/neo.111366
|
[34]
|
McKenzie, L., King, S., Marcar, L., Nicol, S., Dias, S.S., et al. (2010) P53-Dependent Repression of Polo-Like Kinase-1 (PLK1). Cell Cycle (Georgetown, Tex.), 9, 4200-4212. https://doi.org/10.4161/cc.9.20.13532
|
[35]
|
Sun, W., Su, Q., Cao, X., Shang, B., Chen, A., et al. (2014) High Expression of Polo-Like Kinase 1 Is Associated with Early Development of Hepatocellular Carcinoma. International Journal of Genomics, 2014, Article ID: 312130. https://doi.org/10.1155/2014/312130
|
[36]
|
Strebhardt, K. and Ullrich, A. (2006) Targeting Polo-Like Kinase 1 for Cancer Therapy. Nature Reviews. Cancer, 6, 321-330. https://doi.org/10.1038/nrc1841
|
[37]
|
Ando, K., Ozaki, T., Yamamoto, H., Furuya, K., Hosoda, M., et al. (2004) Polo-Like Kinase 1 (PLK1) Inhibits P53 Function by Physical Interaction and Phosphorylation. The Journal of Biological Chemistry, 279, 25549-25561. https://doi.org/10.1074/jbc.M314182200
|
[38]
|
Bouhlal, H., Ouled-Haddou, H., Debuysscher, V., Singh, A.R., Ossart, C., et al. (2016) RB/PLK1-Dependent Induced Pathway by Slamf3 Expression Inhibits Mitosis and Control Hepatocarcinoma Cell Proliferation. Oncotarget, 7, 9832-9843. https://doi.org/10.18632/oncotarget.6954
|
[39]
|
VanHorn, R.D., Chu, S., Fan, L., Yin, T., Du, J., et al. (2010) Cdk1 Activity Is Required for Mitotic Activation of Aurora a during G2/M Transition of Human Cells. The Journal of Biological Chemistry, 285, 21849-21857. https://doi.org/10.1074/jbc.M110.141010
|
[40]
|
Singleton, M.R., Wentzell, L.M., Liu, Y., West, S.C. and Wigley, D.B. (2002) Structure of the Single-Strand Annealing Domain of Human RAD52 Protein. Proceedings of the National Academy of Sciences of the United States of America, 99, 13492-13497. https://doi.org/10.1073/pnas.212449899
|
[41]
|
King, S.I., Purdie, C.A., Bray, S.E., Quinlan, P.R., Jordan, L.B., et al. (2012) Immunohistochemical Detection of Polo-Like Kinase-1 (PLK1) in Primary Breast Cancer Is Associated with Tp53 Mutation and Poor Clinical Outcome. Breast Cancer Research: BCR, 14, R40. https://doi.org/10.1186/bcr3136
|